Three innovative R&D companies have expanded into the state-of-the-art Hexagon Tower in Blackley, signalling a growing interest in science infrastructure outside of Manchester city centre, according to site operator Pioneer Group.
Hexagon Tower, part of Pioneer Group’s wider life sciences network that includes 645 R&D businesses across Europe, is a significant R&D landmark in Manchester, located next to North Manchester General Hospital (NMGH).
Press release
Macomics Team Scores Gold and Raises Over £600 in its Hyper-Triathlon Challenge in aid of Founder Prof. Jeffrey Pollard’s Memorial Fund
AMSBIO has published an informative online article that reviews the importance of culture techniques for induced pluripotent stem cells (iPSCs), which provide an invaluable resource for drug discovery and therapeutic applications.
When using iPSCs for drug discovery and therapeutic applications, it is vital to generate a homogenous culture. The absence of uniformity in iPSC culture can severely compromise the quality and quantity of data generated.
Agreement builds on and complements Daiichi Sankyo and MSD’s shared commitment to develop novel medicines for patients with cancer
Daiichi Sankyo and MSD to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where MSD retains exclusive rights
Sandwich, Kent, UK / 6th August 2024 / Asymchem Laboratories (Tianjin) Co., Ltd. has officially inaugurated its new European development and pilot manufacturing site at Discovery Park in Sandwich, Kent, U.K., marked with a ribbon cutting on Friday 2 August by Dr. Hao Hong, Chairman, Founder, and CEO of Asymchem.
KISS is conducting a 2-minute survey to gather insights on the integration and usage of AI in business and marketing operations across different sectors including, Science, Technology, Education, Agriculture and Professional Services.
We are looking to help identify industry trends, support needs, and guide innovation and anonymised results will be shared with all participants.
Questions we are asking include:
Continuous 2 is an active project aiming to address the growing demand for cost-effective biologics treatments. With the global biopharmaceutical market estimated to grow to 3.9bn by 2024, the industry must act quickly to make these life-changing drugs more accessible to patients, and respond to the demand for flexible manufacturing technology that delivers real-time release of biotherapeutics.
UK Continuous 2 is building on the achievements of two previous projects:
The July edition of our People Pathways newsletter is now available to read here.
You can read about:
✴ New and upcoming One Nucleus courses
✴ Registration open for the next BLSA SIG webinar
✴ Reflections and takeaways from our Neurodiversity webinar
✴ New mentoring opportunities
and more...
French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology.
Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time.